Aldoss, Ibrahim http://orcid.org/0000-0001-9564-4498
Pillai, Raju
Yang, Dongyun
Yang, Lixin
Arslan, Shukaib
Mokhtari, Sally
Malki, Monzr M. Al http://orcid.org/0000-0001-8226-471X
Salhotra, Amandeep
Shahani, Shilpa
Ali, Haris http://orcid.org/0000-0002-9728-7292
Mei, Matthew http://orcid.org/0000-0002-1109-6955
Artz, Andrew
Snyder, David
Afkhami, Michelle
Armenian, Saro http://orcid.org/0000-0003-2604-8603
Stein, Anthony
Marcucci, Guido
Forman, Stephen J.
Nakamura, Ryotaro
Pullarkat, Vinod
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | NCI | Division of Cancer Epidemiology and Genetics, National Cancer Institute (CA033572)
Article History
Received: 12 February 2021
Revised: 10 June 2021
Accepted: 15 June 2021
First Online: 2 July 2021
Competing interests
: I.A. serves on an advisory board with Amgen, KiTE, Abbvie and Agios, he is a consultant for Autolus Therapeutics, and he received research support from MacroGenics and Abbvie. A.S. has served as consultant for Kadmon Corporation and research funding from Celgene. R.N. serves on advisory boards with Merck and Celgene and has a research collaboration with Jazz Pharmaceuticals. A.S. is on the speakers’ bureau for Amgen, Celgene, and Stemline. G.M. is on the speakers’ bureau for Abbvie. V.P. has served on the advisory boards for Abbvie and Jazz Pharmaceuticals and is member of speakers’ bureau for Jazz Pharmaceuticals, Amgen, Novartis, and Abbvie. The remaining authors have no relevant conflicts of interest to declare.